NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced positive ...
Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...
A new study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be ...
Zidesamtinib targets ROS1-positive NSCLC, showing promise in overcoming resistance mutations and CNS metastases with brain penetrance. The ARROS-1 trial demonstrated significant response rates in TKI ...
NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational ROS-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback